Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Summary

The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.

Timeline

Start

2010-11-09

Primary completion

2011-10-15

Completion

2011-10-15

Drugs

Indications